This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Herceptin
  • /
  • A Study To Evaluate the Efficacy and Safety Of Ate...
Clinical trial

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)

Read time: 3 mins
Last updated:11th Jan 2019
Identifier: NCT03726879

This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 224 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Actual Study Start Date: January 11, 2019
Estimated Primary Completion Date: April 21, 2021
Estimated Study Completion Date: September 20, 2023

Arms:
- Experimental:
Atezolizumab +ddAC-PacHP
- Placebo Comparator: Placebo + ddAC-PacHP

Category Value
Date last updated at source 2019-07-23
Study type(s) Interventional
Expected enrolment 224
Study start date 2019-01-11
Estimated primary completion date 2021-04-21

View full details